NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

Sep 26, 2023 | Press Releases

CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Reports Second Quarter 2023 Financial Results

Sep 21, 2023 | Press Releases

CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

Sep 13, 2023 | Press Releases

CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

Sep 12, 2023 | Press Releases

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

Aug 29, 2023 | Press Releases

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in...

NeurAxis Highlights Strength of its Board of Directors

Aug 24, 2023 | Press Releases

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) — NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions...